FY2025 EPS Estimates for Metsera Cut by Cantor Fitzgerald

Metsera, Inc. (NASDAQ:MTSR) – Equities researchers at Cantor Fitzgerald lowered their FY2025 earnings per share estimates for shares of Metsera in a research report issued on Thursday, March 27th. Cantor Fitzgerald analyst P. Agrawal now anticipates that the company will post earnings per share of ($3.58) for the year, down from their prior estimate of ($3.38). Cantor Fitzgerald currently has a “Overweight” rating on the stock.

Metsera (NASDAQ:MTSR) last issued its quarterly earnings data on Wednesday, March 26th. The company reported ($3.52) earnings per share for the quarter.

Other research analysts have also issued research reports about the stock. Evercore ISI assumed coverage on shares of Metsera in a research note on Tuesday, February 25th. They issued an “outperform” rating on the stock. Bank of America started coverage on Metsera in a report on Tuesday, February 25th. They issued a “buy” rating and a $38.00 price objective for the company. Finally, Guggenheim started coverage on shares of Metsera in a research note on Tuesday, February 25th. They set a “buy” rating and a $56.00 price objective on the stock.

Metsera Trading Down 6.7 %

Shares of NASDAQ:MTSR opened at $28.00 on Monday. Metsera has a 1-year low of $23.08 and a 1-year high of $32.81.

About Metsera

Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.